drugset
drugset / Trial / NCT02205242

BACE Trial Substudy 1 - PROactive Substudy

NCT02205242 ↗

Phase 3 Completed 60 enrolled Wim Janssens Pro-Active Medical Pty Ltd · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

A first sub-analysis of the BACE trial will address physical activity levels in a subgroup of the intervention study with portable validated activity monitors.

Timeline

Start
2014-09
Primary completion
2018-04
Completion
2020-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 250 mg Oral

Indications

chronic obstructive pulmonary disease